ARIAD Pharmaceuticals just announced the initiation of the Phase II trial of Ponatinib (brand name = Iclusig®) in adult patients with metastatic and/or unresectable gastrointestinal stromal tumours (GIST). The trial is designed to provide initial clinical data evaluating the efficacy and safety of Ponatinib in patients with GIST following failure of prior tyrosine kinase inhibitor (TKI) therapy.
With the disreimbursement of Trabectedin in France, sarcoma patients are facing a dramatic situation. From 2008, when the EMA and the French Health authorities approved Trabectedin, to 2012, Trabectedin was reimbursed by the French Social Security. Since the beginning of 2013 this drug is not reimbursed anymore in sarcomas. Subsequently, for French doctors it is not possible anymore to prescribe Trabectedin to sarcoma patients although this drug remains, for the physicians of the French Sarcoma Group and those of the European Society of Medical Oncology (ESMO), the "gold standard" in the treatment of this disease. SPAEN would like to support the French sarcoma patients and physicians in their actions by collecting supportive signatures from other sarcoma SPAEN member organizations and sarcoma patients.
At 25th of Feb. 2013 the U.S. Food and Drug Administration expanded the approved use of Bayer Pharmaceutical's drug Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to other FDA-approved treatments for this disease. Stivarga was approved in September 2012 to treat colorectal cancer.
For the first time ever, scientists have identified a specific genetic risk factor that, when present, significantly increases the chances that an individual will develop chordoma. This discovery – a milestone outcome of the Chordoma Foundation’s significant investment in the Chordoma Genome Project over the past three years – provides unprecedented insight into how chordoma forms, and potentially how to effectively treat it.
The multi-tyrosine kinase inhibitor regorafenib significantly delays disease progression in virtually all subgroups of patients with gastrointestinal stromal tumor (GIST) in the second-line setting, and may even confer benefits when continued after progression, according to subgroup and post-progression analyses of the phase III GRID trial presented at the ESMO 2012 Congress. The current exploratory analyses were presented at ESMO 2012 by Peter Reichardt, MD, PhD, of HELIOS Klinikum in Bad Saarow, Germany. Read more at OncLive. At OncLive there are also related articles and videos on different aspects of GIST treatment available.
Rare cancers represent more than 20% of all cancer cases diagnosed in the EU each year and affect more than 4 million people in the EU. Patients with rare cancers – such as Sarcomas, GIST and Desmoids - are faced with particular challenges, including late or incorrect diagnosis, difficulties finding clinical expertise and accessing appropriate treatments, difficulties carrying out clinical studies due to the small number of patients, possible lack of interest in developing new therapies, high uncertainty in clinical decision-making, and the scarcity of available registries and tissue banks.